Skip to main content
ANAGENICS LIMITED logo

ANAGENICS LIMITED — Investor Relations & Filings

Ticker · AN1 ISIN · AU0000198095 ASX Manufacturing
Open in API
Filings indexed 1,067 across all filing types
Latest filing 2015-06-28 Regulatory Filings
Country AU Australia
Listing ASX AN1

About ANAGENICS LIMITED

https://anagenics.com

Anagenics Limited is a health and wellness company focused on the development and commercialization of science-based anti-aging and longevity solutions. The company specializes in the research and distribution of clinically validated products targeting hair loss and skin health. Its core portfolio includes the évolis brand, which utilizes proprietary FGF5 inhibitor technology to promote hair growth and improve hair health. Through its subsidiaries, such as Advangen and BLC Cosmetics, the company manages a diverse range of premium skincare and wellness brands. Anagenics operates across international markets, providing consumer-facing products and professional-grade treatments backed by scientific research. The company's strategic focus remains on expanding its presence in the global beauty-tech and wellness sectors by leveraging its intellectual property and distribution networks.

Recent filings

Filing Released Lang Actions
US Patent for Anti-Midkine Antibodies Granted 2 pages 98.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement regarding the granting of a US patent for anti-midkine antibodies by Cellmid Limited. It focuses on intellectual property and patent rights, describing the commercial and therapeutic significance of the patent. There is no financial data, earnings information, management discussion, or regulatory compliance content. The document is a corporate announcement about a patent grant, which does not fit into financial report categories like Annual Report, Earnings Release, or Interim Report. It is not a regulatory filing or certification either. The best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2015-06-28 English
Cellmid Announces Brain Cancer Program 3 pages 107.0KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Cellmid Limited dated 23 June 2015. It details a new research collaboration to test anti-MK antibodies for treating brain cancer, specifically glioblastoma. The content focuses on the scientific and strategic aspects of the collaboration, describing the research goals, background on the disease, and the company's plans. There are no financial statements, no regulatory certifications, no voting results, no management changes, no earnings data, and no mention of report attachments or filings. The document is a corporate announcement about a research collaboration and development update. This fits best under the category of a general regulatory announcement or company update that does not fit other specific categories. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length (7364 characters) and content confirm it is not a brief report publication announcement or a full financial report.
2015-06-22 English
Cellmid Invited to Present at Breakfast @ BIO 19 pages 2.2MB
Investor Presentation Classification · 95% confidence The document is an ASX announcement from Cellmid Limited dated June 2015. It details the company's invitation to present at the BIO 2015 Convention, including a presentation titled "Breakfast at BIO". The content includes company background, business overview, management team, product pipeline, and forward-looking statements. It also mentions that presentation slides are attached. The document is a detailed investor presentation focusing on company strategy, products, and market position rather than a financial report or regulatory filing. It is not a full annual or interim report, nor an earnings release or audit report. It is not a voting result, capital update, or legal proceeding. The presence of presentation slides and detailed company information aligns with the definition of an Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2015-06-16 English
Positive Toxicology Study Results for CAB102 2 pages 99.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Cellmid Limited dated 15 June 2015. It reports on the results of pre-clinical toxicology studies for a drug candidate (CAB102), describing safety outcomes and study details. The content is focused on announcing study results and the implications for clinical development. There are no financial statements, regulatory certifications, or detailed financial data. The document is a corporate announcement about a scientific study result rather than a formal financial report or regulatory filing. It is not a full annual or interim report, nor a call transcript or management discussion. The document fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about a drug development milestone and safety study results, which do not fit other specific categories.
2015-06-14 English
Cellmid Signs Agreement with Maywufa 2 pages 82.2KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement about a supply agreement signed between Cellmid Limited and Taiwanese company Maywufa for hair growth products. It discusses the terms of the agreement, product details, market information, and company background. There are no financial statements, quarterly or annual results, or regulatory filings referenced. The document is a corporate announcement about a business agreement and strategic partnership, not a financial report or regulatory filing. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to a business development and supply agreement that impacts the company's commercial activities and potential revenue streams.
2015-06-01 English
Director Appointment / Resignation 2 pages 63.2KB
Board/Management Information Classification · 100% confidence The document is an ASX announcement dated 26 May 2015 from Cellmid Limited regarding the appointment and resignation of directors on its Board. It details the resignation of two directors and the appointment of a new non-executive director, including their backgrounds and contributions. There is no financial data, earnings information, or report content. The focus is solely on changes in the company's board of directors. Therefore, this document fits the category of Board/Management Information (MANG). The document length is 4889 characters, which is sufficient to contain substantive information about board changes rather than a brief notice or report publication announcement.
2015-05-25 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.